Sector News

J&J eyes immuno-oncology with 15 R&D assets

October 19, 2016
Life sciences

Johnson & Johnson loves to make ambitious pronouncements for itself. Its latest was a commitment to submit to the FDA applications for 10 potential blockbusters within five years by the end of 2019. It fleshed out where it is on those 2015 plans on an Oct. 18 conference call.

In the longer term, the pharma is also making some overtures in immuno-oncology, an area that hasn’t explicitly been a major part of its strategy. J&J has been investing in “four critical areas including vaccines, T cell checkpoint inhibitors, T cell redirection and myeloid mechanisms of action,” said the company’s global head of pharmaceutical R&D, Dr. William Hait, during the call.

He said the pharma has 15 immuno-oncology assets in development, including eight that are already in the clinic.

“While we did not explicitly address immuno-oncology during our 2015 Pharmaceutical Business Review, we continue to make significant progress in this area,” said Hait. “We currently have 15 immuno-oncology assets in development, including eight that are in the clinic. Recently, we uncovered an important additional mechanism of action of Darzalex to the immune-mediated through the depletion of immunosuppressive myeloid and lymphoid populations including a previously unrecognized supersuppressor CD38 positive T-reg population as well as activation of CD8 and CD4 positive effector T cells. These results provide the impetus for exploring Darzalex in indications beyond key malignancies in solid tumors.”

Darzalex is the first of the 10 new potential blockbuster molecular entities J&J committed to filing; the CD38 monoclonal antibody to treat double refractory multiple myeloma was approved by the FDA last year. Up next is sirukumab to treat rheumatoid arthritis, for which it has already filed, and guselkumab for psoriasis for which it plans to file before year end.

On the immuno-oncology front, J&J partnered earlier this year to take its early stage antigen-presentation treatment into Phase II testing in combination with Opdivo (nivolumab) from Bristol-Myers Squibb.

Last year, Swedish startup Alligator Biosciences also did an immuno-oncology deal with J&J worth up to $700 million in milestones and royalties. It has a CD40-targeting ADC-1013, an antibody designed to spur a T-cell attack on cancer.

J&J also partnered with another startup in that time frame–San Diego,CA-based Poseida Therapeutics–to discover and develop new CARs, T cells and natural killer cells adapted with chimeric antigen receptors and targeted at cancer cells.

Slow growth in hepatitis C and the promise from Pfizer that a biosimilar Remicade is coming to market later this year were both downplayed by J&J. Remicade is by far J&J’s biggest drug with $5.3 billion in sales during the first three quarters of this year.

By Stacy Lawrence

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach